Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry

X Lu, L Yu, Z Zhang, X Ren, JB Smaill… - Medicinal research …, 2018 - Wiley Online Library
Both the first‐generation reversible epidermal growth factor receptor (EGFR) inhibitors
gefitinib and erlotinib and the second‐generation covalent epidermal growth factor receptor …
被引用次数：138 相关文章

Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry

X Lu, L Yu, Z Zhang, X Ren… - Medicinal research …, 2018 - pubmed.ncbi.nlm.nih.gov
Both the first-generation reversible epidermal growth factor receptor (EGFR) inhibitors
gefitinib and erlotinib and the second-generation covalent epidermal growth factor receptor …

Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry.

X Lu, L Yu, Z Zhang, X Ren, JB Smaill… - Medicinal Research …, 2018 - europepmc.org
Both the first-generation reversible epidermal growth factor receptor (EGFR) inhibitors
gefitinib and erlotinib and the second-generation covalent epidermal growth factor receptor …

[引用][C] Targeting EGFRL858R/T790Mand EGFRL858R/T790M/C797Sresistance mutations in NSCLC: Current developments in medicinal chemistry

X Lu, L Yu, Z Zhang, X Ren, JB Smaill… - Medicinal Research …, 2018 - cir.nii.ac.jp
Targeting EGFR<sup>L858R/T790M</sup>and EGFR<sup>L858R/T790M/C797S</sup>resistance
mutations in NSCLC: Current developments in medicinal chemistry | CiNii Research CiNii 国立 …

Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry

X Lu, L Yu, Z Zhang, X Ren, JB Smaill… - Medicinal Research …, 2018 - infona.pl
Both the first‐generation reversible epidermal growth factor receptor (EGFR) inhibitors
gefitinib and erlotinib and the second‐generation covalent epidermal growth factor receptor …